Media headlines about Sierra Oncology (NASDAQ:SRRA) have trended somewhat negative on Friday, Accern Sentiment reports. Accern rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sierra Oncology earned a media sentiment score of -0.07 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 47.492953260673 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:
A number of research firms have recently commented on SRRA. BidaskClub upgraded shares of Sierra Oncology from a “hold” rating to a “buy” rating in a research note on Saturday, June 16th. ValuEngine upgraded shares of Sierra Oncology from a “hold” rating to a “buy” rating in a research note on Wednesday, May 2nd. Finally, Zacks Investment Research downgraded shares of Sierra Oncology from a “hold” rating to a “sell” rating in a research note on Friday, March 2nd.
NASDAQ:SRRA traded down $0.14 during mid-day trading on Friday, hitting $3.30. The stock had a trading volume of 308,737 shares, compared to its average volume of 596,719. Sierra Oncology has a twelve month low of $1.12 and a twelve month high of $4.09. The company has a market capitalization of $250.43 million, a P/E ratio of -3.93 and a beta of 2.55.
Sierra Oncology (NASDAQ:SRRA) last issued its earnings results on Thursday, May 10th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.02. equities research analysts anticipate that Sierra Oncology will post -0.7 earnings per share for the current year.
Sierra Oncology Company Profile
Sierra Oncology, Inc, a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer.
Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.